Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Decreases By 53.3%

enGene Holdings Inc. (NASDAQ:ENGNW) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 700 shares, a decline of 53.3% from the June 15th total of 1,500 shares. Based on an average daily volume of 6,400 shares, the short-interest ratio is presently 0.1 days.

enGene Trading Up 5.3 %

ENGNW stock traded up $0.06 during mid-day trading on Friday, hitting $1.20. 350 shares of the company were exchanged, compared to its average volume of 26,917. enGene has a 1-year low of $0.39 and a 1-year high of $6.50. The business has a 50 day simple moving average of $2.35 and a 200-day simple moving average of $2.80.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.